{
  " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test": {
    "Document Type": "Summary of Product Characteristics (SmPC)",
    "Product Name": "Praluent",
    "Active Substance(s)": "alirocumab",
    "Strength": "75 mg solution (1 ml), 150 mg solution (1 ml), 300 mg solution (2 ml)",
    "Pharmaceutical Form": "Solution for injection",
    "Route of Administration": "Subcutaneous",
    "Indications": "Primary hypercholesterolaemia and mixed dyslipidaemia; established atherosclerotic cardiovascular disease",
    "Posology": "Adults (init: 75 mg every 2 weeks, may increase to 150/300 mg); Paediatric (8+ years: 150/300 mg Q2W or Q4W based on weight); Renal/hepatic impairment: no adjustment needed for mild/moderate",
    "Contraindications": "Hypersensitivity to alirocumab or excipients",
    "Special Warnings and Precautions": "Traceability, allergic reactions (angioedema, hypersensitivity vasculitis), local injection site reactions, possible accumulation of anti-drug antibodies (ADAs), concurrent use with statins/reduced exposure, monitoring for low LDL-C.",
    "Marketing Authorisation Holder": "Sanofi Winthrop Industrie",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "23 September 2015",
    "Date of Latest Renewal": "2 June 2020",
    "Shelf Life": "3 years for some presentations (e.g., 75 mg pen), 2 years for others (e.g., 150 mg pen)",
    "Storage Conditions": "Store in refrigerator (2\u00b0C to 8\u00b0C), protect from light, may be stored below 25\u00b0C for up to 30 days post-refrigerator removal, discard after 30 days.",
    "Package Description": "Pre-filled pens (blue cap), pre-filled syringes (green/grey plunger), various pack sizes (1, 2, 3, 6 pens/syringes)",
    "Legal Category": "Prescription only",
    "ATC Code": "C10AX14",
    "Manufacturers": "Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC, Sanofi Winthrop Industrie, Sanofi-Aventis Deutschland GmbH, Genzyme Ireland Ltd",
    "Excipients": "histidine, sucrose, polysorbate 20, water for injections",
    "File Name": " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test",
    "Template ID": "1757923113628"
  },
  "https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1": {
    "Document Type": "Not found",
    "Product Name": "Not found",
    "Active Substance(s)": "Not found",
    "Strength": "Not found",
    "Pharmaceutical Form": "Not found",
    "Route of Administration": "Not found",
    "Indications": "Not found",
    "Posology": "Not found",
    "Contraindications": "Not found",
    "Special Warnings and Precautions": "Not found",
    "Marketing Authorisation Holder": "Not found",
    "Marketing Authorisation Number": "Not found",
    "Date of First Authorisation": "Not found",
    "Date of Latest Renewal": "Not found",
    "Shelf Life": "Not found",
    "Storage Conditions": "Not found",
    "Package Description": "Not found",
    "Legal Category": "Not found",
    "ATC Code": "Not found",
    "Manufacturers": "Not found",
    "Excipients": "Not found",
    "File Name": "https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1",
    "Template ID": "1757930051220"
  },
  " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1": {
    "Document Type": "Summary of Product Characteristics",
    "Product Name": "Apixaban Accord",
    "Active Substance(s)": "apixaban",
    "Strength": "2.5 mg, 5 mg",
    "Pharmaceutical Form": "film-coated tablet",
    "Route of Administration": "oral use",
    "Indications": "prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, prevention of recurrent deep vein thrombosis and pulmonary embolism",
    "Posology": "2.5 mg twice daily, 5 mg twice daily",
    "Contraindications": "hypersensitivity to apixaban or any of the excipients, active clinically significant bleeding, hepatic disease associated with coagulopathy and clinically relevant bleeding risk",
    "Special Warnings and Precautions": "increased risk of bleeding, interaction with other medicinal products affecting haemostasis, use with caution in conditions with increased risk of haemorrhage",
    "Marketing Authorisation Holder": "Accord Healthcare S.L.U.",
    "Marketing Authorisation Number": "EU/1/20/1458/001, EU/1/20/1458/003, EU/1/20/1458/004, EU/1/20/1458/006, EU/1/20/1458/008, EU/1/20/1458/010, EU/1/20/1458/012, EU/1/20/1458/014, EU/1/20/1458/041, EU/1/20/1458/043",
    "Date of First Authorisation": "23 July 2020",
    "Date of Latest Renewal": "\"Date of Latest Renewal\": \"Not found\",",
    "Shelf Life": "3 years",
    "Storage Conditions": "store in a cool, dry place, protected from light",
    "Package Description": "film-coated tablets, 10, 14, 20, 28, 56, 60, 100, 112, 168, 200 film-coated tablets",
    "Legal Category": "\"Legal Category\": \"Not found\",",
    "ATC Code": "\"ATC Code\": \"Not found\",",
    "Manufacturers": "LABORATORI FUNDACI\u00d3 DAU, Accord Healthcare Polska Sp. z.o.o., Pharmadox Healthcare Limited, Accord Healthcare single member S.A.",
    "Excipients": "lactose, cellulose microcrystalline, croscarmellose sodium, sodium laurilsulfate, magnesium stearate, lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172), iron oxide red (E172)",
    "File Name": " https://graph.microsoft.com/v1.0/sites/slickbitai.sharepoint.com,b749c6f0-ede8-48b2-9420-ce94ca741683,876dc7c6-5b74-44d2-9d5c-a40b9e5cbf21/drive/root:/application_test1",
    "Template ID": "1757934759488"
  }
}